Group items tagged

The purpose of this funding opportunity announcement (FOA) is twofold: (1) to stimulate basic and mechanistic science that facilitates the development of effective probiotics or pre-/probiotic combinations of relevance to human health and disease; and (2) determine biological outcomes for the evaluation of efficacy of pre/probiotics in appropriate test systems and animal models. This FOA encourages basic and mechanistic studies using in vitro, in vivo, ex vivo, and in silico models that focus on prebiotic/probiotic strain selectivity, interaction, and function. It will also encourage inter and multidisciplinary collaborations among scientists in a wide range of disciplines including nutritional science, immunology, microbiomics, genomics, other '-omic' sciences, biotechnology, and bioinformatics.

The purpose of this funding opportunity announcement (FOA) is twofold: (1) to stimulate basic and mechanistic science that facilitates the development of effective probiotics or pre-/probiotic combinations of relevance to human health and disease; and (2) determine biological outcomes for the evaluation of efficacy of pre/probiotics in appropriate test systems and animal models. This FOA encourages basic and mechanistic studies using in vitro, in vivo, ex vivo, and in silico models that focus on prebiotic/probiotic strain selectivity, interaction, and function. It will also encourage inter and multidisciplinary collaborations among scientists in a wide range of disciplines including nutritional science, immunology, microbiomics, genomics, other '-omic' sciences, biotechnology, and bioinformatics.

The purpose of this funding opportunity announcement (FOA) is twofold: (1) to stimulate basic and mechanistic science that facilitates the development of effective probiotics or pre-/probiotic combinations of relevance to human health and disease; and (2) determine biological outcomes for the evaluation of efficacy of pre/probiotics in appropriate test systems and animal models. This FOA encourages basic and mechanistic studies using in vitro, in vivo, ex vivo, and in silico models that focus on prebiotic/probiotic strain selectivity, interaction, and function. It will also encourage inter and multidisciplinary collaborations among scientists in a wide range of disciplines including nutritional science, immunology, microbiomics, genomics, other '-omic' sciences, biotechnology, and bioinformatics.

The purpose of this funding opportunity announcement (FOA) is twofold: 1. to accelerate translational and clinical Phase I and II a/b safety and efficacy studies for substantiating measurable functional benefits of probiotic/prebiotic components and/or their combinations; and; 2. to understand the underlying mechanisms of their action(s), and variability in responses to these interventions. This FOA calls for interdisciplinary collaborations across scientific disciplines engaged in microbiome and pro/prebiotic research including, but not limited to: nutritional science, microbiology, virology, microecology and microbiome, genomics, immunology, computational biology, chemistry, bioengineering, as well as integration of omics and computational approaches in DNA technologies.

Through the program, two grants of $25,000 will be awarded to graduate student researchers interested in exploring the gut microbiome, probiotics, and yogurt and how they help support and maintain human health and wellness. Topics may include the role that probiotics or yogurt play on brain function, growth and development, digestive health, weight management or heart health; and factors such as foods or nutrients that influence the gut microbiome. The grant is not designed for the investigation of disease treatment or clinical management and should focus on health and wellness, long-term health and longevity, growth and development, and/or performance.

The goal of this funding opportunity announcement (FOA) is to support pilot testing of natural products (i.e., botanicals, dietary supplements, and probiotics), which have a strong scientific premise to justify further clinical testing. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. This FOA is not intended to support a randomized controlled trial (RCT) to test the efficacy of the natural product on clinical outcomes.  Rather, the data collected should be used to fill gaps in scientific knowledge and provide the information necessary to develop a competitive full-scale clinical trial.

The goal of this funding opportunity announcement (FOA) is to support pilot testing of natural products (i.e., botanicals, dietary supplements, and probiotics), which have a strong scientific premise to justify further clinical testing. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. This FOA is not intended to support a randomized controlled trial (RCT) to test the efficacy of the natural product on clinical outcomes.  Rather, the data collected should be used to fill gaps in scientific knowledge and provide the information necessary to develop a competitive full-scale clinical trial.

The goal of this funding opportunity announcement (FOA) is to support pilot testing of natural products (i.e., botanicals, dietary supplements, and probiotics), which have a strong scientific premise to justify further clinical testing. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. This FOA is not intended to support a randomized controlled trial (RCT) to test the efficacy of the natural product on clinical outcomes.  Rather, the data collected should be used to fill gaps in scientific knowledge and provide the information necessary to develop a competitive full-scale clinical trial.

The goal of this funding opportunity announcement (FOA) is to support pilot testing of natural products (i.e., botanicals, dietary supplements, and probiotics), which have a strong scientific premise to justify further clinical testing. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. This FOA is not intended to support a randomized controlled trial (RCT) to test the efficacy of the natural product on clinical outcomes.  Rather, the data collected should be used to fill gaps in scientific knowledge and provide the information necessary to develop a competitive full-scale clinical trial.

The purpose of this funding opportunity announcement (FOA) is twofold: 1. to accelerate translational and clinical Phase I and II a/b safety and efficacy studies for substantiating measurable functional benefits of probiotic/prebiotic components and/or their combinations; and; 2. to understand the underlying mechanisms of their action(s), and variability in responses to these interventions. This FOA calls for interdisciplinary collaborations across scientific disciplines engaged in microbiome and pro/prebiotic research including, but not limited to: nutritional science, microbiology, virology, microecology and microbiome, genomics, immunology, computational biology, chemistry, bioengineering, as well as integration of omics and computational approaches in DNA technologies. This FOA will not support phase III clinical trials.

Alcohol abuse has long been associated with increased susceptibility to opportunistic infections. This association has led to extensive research demonstrating that alcohol abuse has a profound and negative impact on immune cell number and function and development of immune defense against pathogens. This pattern of drinking differentially affects the outcome of alcohol abuse: binge alcohol consumption suppresses host innate immune defense; chronic alcohol consumption suppresses most immune functions including phagocytic activity of macrophages and development of adaptive immune defense, yet paradoxically activates chronic inflammation.  Cumulative evidence now also supports a role for alcohol-induced immune alterations, in particular inflammation, in a wide range of alcohol related illnesses involving organ or tissue injury. In some cases, interventions against such alcohol-induced immune dysfunctions, such as anti-oxidant supplements and probiotics, are found to be effective in improving the clinical outcome. A comprehensive understanding of alcohol-induced immune dysfunctions and the underlying mechanisms is critical for developing effective diagnostic, preventive, and treatment approaches.  

This Funding Opportunity Announcement (FOA) invites applications from researchers with broad expertise to study the consequences of alcohol consumption on immune function with a goal toward improving the outcome of patients who abuse alcohol. Alcohol abuse has long been associated with increased susceptibility to opportunistic infections. This association has led to extensive research demonstrating that alcohol abuse has a profound and negative impact on immune cell number and function and development of immune defense against pathogens. This pattern of drinking differentially affects the outcome of alcohol abuse: binge alcohol consumption suppresses host innate immune defense; chronic alcohol consumption suppresses most immune functions including phagocytic activity of macrophages and development of adaptive immune defense, yet paradoxically activates chronic inflammation. Cumulative evidence now also supports a role for alcohol-induced immune alterations, in particular inflammation, in a wide range of alcohol related illnesses involving organ or tissue injury. In some cases, interventions against such alcohol-induced immune dysfunctions, such as anti-oxidant supplements and probiotics, are found to be effective in improving the clinical outcome. A comprehensive understanding of alcohol-induced immune dysfunctions and the underlying mechanisms is critical for developing effective diagnostic, preventive, and treatment approaches.

Established in 2012, the program has expanded to include the gut microbiome in recognition of its remarkable potential on the human body - including immune health, brain health, and proper digestion and absorption. To date, the program has supported research on the use of foods as a delivery vector for beneficial bacteria, technology for studying the adaptation of fermentative microbes to milk, the effects of protein fermentation on the human microbiota and digestive health, and the relationship between probiotics, the gut microbiome and brain function.

The National Center for Complementary and Integrative Health (NCCIH) announces the availability of funds for Administrative Supplements or Urgent Competitive Revisions to promote research on the effects of natural products alone or in combination with other complementary and integrative health approaches on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NCCIH is particularly interested in projects focusing on the therapeutic and/or mechanistic effects on SARS-CoV-2/COVID-19 of natural product-based complementary remedies including, but not limited to: herbal therapies, vitamins, supplements, probiotics, microbial therapies, and Chinese medicine herbal preparations.